Company Overview
Fortress Biotech, Inc. operates as a biopharmaceutical company dedicated to the development and commercialization of specialized biopharmaceutical products, with a specific focus on the dermatology sector. The company markets distinct therapeutic agents such as Emrosi, a minocycline hydrochloride extended-release capsule designed for the treatment of rosacea, and Qbrexza, a medicated clotrimazole formulation. This entity functions within the broader Healthcare sector, specifically navigating the competitive landscape of the Biotechnology industry where innovation in drug formulation and clinical efficacy are paramount. The company's current operational scale is defined by a market capitalization of $71.82M, an annual revenue of $62.30M, and a workforce comprising 101 employees. These financial and personnel metrics indicate that Fortress Biotech, Inc. occupies a small-cap position within the biotechnology space, suggesting a firm that is likely in a growth or development phase rather than a mature, cash-cow stage typical of larger pharmaceutical giants.
Financial Health
The company reports a trailing twelve-month revenue of $62.30M against a net income of $-5,336,000 and an EBITDA of $-79,903,000, highlighting a significant divergence between top-line generation and bottom-line profitability. The substantial gap between revenue and net income reveals a cost structure where operating expenses, likely driven by research and development or commercialization costs, heavily outweigh gross profits, resulting in a net loss despite positive sales. Free cash flow stands at $-53,357,124, which indicates that the company is consuming cash reserves to fund its operations and growth initiatives rather than generating excess liquidity for dividends or acquisitions. Analyzing the margin structure, the gross margin is 32.0%, reflecting the profitability of production relative to costs, while the operating margin is -38.6% and the profit margin is 6.4%, illustrating that high operating expenses are currently eroding overall profitability on a pre-tax basis. The company holds $86.22M in cash against $68.29M in debt, resulting in a debt-to-equity ratio of 104.77, which suggests a leveraged balance sheet where liabilities slightly exceed equity. Despite the leverage, the current ratio of 2.19 indicates a conservative stance on short-term liquidity, as the company possesses more than twice the current assets necessary to cover its current liabilities. Furthermore, the return on equity is -205.3% and the return on assets is -34.3%, metrics that reveal management is currently utilizing shareholder capital and assets to generate negative returns, a common characteristic for biotech firms in the early stages of product commercialization or clinical development.
Valuation Assessment
The trailing P/E ratio is listed as N/A and the forward P/E is N/A, implying that standard earnings-based valuation multiples cannot be applied due to the absence of positive net income. The price-to-book ratio is 7.43, indicating that the market values the company at a significant premium over its tangible book value, likely reflecting the value placed on its intangible assets, intellectual property, and pipeline potential. The price-to-sales ratio is 1.15, while the EV/EBITDA stands at -5.09, suggesting that alternative valuation metrics rely heavily on revenue multiples rather than earnings multiples to assess the company's worth. The stock has traded between a 52-week low of $4.72 and a 52-week high of $14.64, meaning the current market price sits within this historical range but does not approach the recent peak. The beta value is 1.41, which signifies that the stock exhibits higher price volatility relative to the broader market, moving 41% more than the benchmark index during periods of market fluctuation.
Growth & Income
Revenue growth year-over-year is 20.5%, whereas earnings growth is N/A due to the company's current net loss status, indicating that top-line expansion is the primary driver of value creation rather than immediate profit improvement. As a non-dividend payer with a dividend yield of N/A and a payout ratio of N/A, the company does not distribute cash to shareholders but instead reinvests its earnings and cash reserves into research, development, and commercialization efforts to fuel future expansion. This reinvestment strategy is typical for biotechnology firms that prioritize building a robust pipeline and securing regulatory approvals over providing immediate income to investors. Overall, the growth and income profile is characterized by strong top-line expansion without current profitability, relying on capital markets or existing cash balances to sustain operations until the business achieves consistent positive earnings.